Random amplified polymorphic DNA assay as a rapid tool in screening for Neisseria meningitidis serogroup C isolates

S Schmink1, M W Reeves, B Plikaytis

  • 1Meningitis and Special Pathogens Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. zma6@cdc.gov

Insights

A new DNA assay can rapidly screen for Neisseria meningitidis serogroup C (NMSC) isolates of electrophoretic type 24 (ET-24), a common cause of US meningococcal disease outbreaks. This method shows promise for faster identification of disease-causing NMSC strains.

Area of Science:

  • Microbiology
  • Molecular Biology
  • Epidemiology

Background:

  • Neisseria meningitidis serogroup C (NMSC) isolates, specifically electrophoretic type 24 (ET-24), are a primary cause of meningococcal disease outbreaks and sporadic cases in the United States.
  • Accurate and rapid identification of NMSC ET-24 is crucial for effective disease control and outbreak management.

Purpose of the Study:

  • To evaluate the utility of a random amplified polymorphic DNA (RAPD) assay as a rapid screening tool for NMSC ET-24 isolates.
  • To determine the sensitivity and specificity of the RAPD assay for identifying ET-24 strains.

Main Methods:

  • A total of 199 NMSC isolates, representing 51 different electrophoretic types (ETs), were tested using the RAPD assay.
  • Two specific primers, P1 and P5, were employed in the RAPD assay, and the resulting DNA patterns were analyzed.

Main Results:

  • The RAPD assay demonstrated a sensitivity of 88% and a specificity of 87% in identifying NMSC ET-24 isolates when patterns from primers P1 and P5 were analyzed together.
  • This indicates a high degree of accuracy in distinguishing ET-24 isolates from other NMSC electrophoretic types.

Conclusions:

  • The random amplified polymorphic DNA assay is a viable and rapid method for screening Neisseria meningitidis serogroup C isolates for electrophoretic type 24.
  • The assay's performance, particularly with primers P1 and P5, supports its potential application in clinical and epidemiological settings for faster identification of key NMSC strains.